Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
NCT07799571Phase 1Not yet recruiting
- Sponsor
- Natasha Archer
- Start
- Jan 2027
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine in vaso-occlusive crisis (VOC), sponsored by Natasha Archer. Primary endpoint: Incidence of Protocol-Defined Safety Events at 48 hours. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
buprenorphine
03
Conditions
vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT07799571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799571.